Major Drug Pricing Developments:

Trump Drug Pricing Deals Could Lower Costs for Major Prostate Cancer Treatments

AstraZeneca, Pfizer agreements promise "most-favored-nation" pricing on Lynparza, Xtandi, and other therapies—but experts question real-world impact

October 11, 2025 — IPCSG Newsletter

Two of the world's largest pharmaceutical companies have agreed to lower prescription drug prices for U.S. patients in deals that could significantly affect the cost of several leading prostate cancer treatments, though the actual savings for most patients remain uncertain.

President Donald J. Trump announced on October 10 that AstraZeneca became the second major pharmaceutical company to bring American drug prices in line with the lowest paid by other developed nations, known as most-favored-nation (MFN) pricing, following a similar September agreement with Pfizer. The deals cover drugs including Lynparza, Xtandi, and Talzenna—medications that collectively generate billions in annual sales and represent critical treatment options for men with advanced prostate cancer.

The Problem: Americans Pay Far More

The United States has less than five percent of the world's population yet funds around three quarters of global pharmaceutical profits, with drug manufacturers deeply discounting their products to access foreign markets and subsidizing those discounts through enormously high prices in the United States.

The disparity is stark for prostate cancer drugs. Xtandi costs U.S. patients about $156,000 a year on average—five times more than in Japan and Canada, with the drug costing about $45 per capsule in Denmark compared to $113-130 in the U.S. Lynparza is priced from $8,486.56 for 60 tablets of the 150 mg formulation.

What the Deals Promise

Under the agreements, both companies will charge most-favored-nation pricing to Medicaid while guaranteeing such pricing on newly launched drugs, matching the lowest price offered in other developed nations. AstraZeneca stated it will allow eligible patients with prescriptions for chronic diseases to purchase drugs directly at discounts of up to 80% off list prices.

Both companies will participate in a new government website, TrumpRx.gov, scheduled to launch in early 2026. The government-operated website will function as a search portal where consumers can look up prescriptions and be redirected to the pharmaceutical manufacturer's own direct-to-consumer platform to complete purchases.

As part of their agreements, both companies received three-year reprieves on certain pharmaceutical import tariffs, with AstraZeneca announcing $4.5 billion for a new Virginia manufacturing plant as part of $50 billion in U.S. investments by 2030.

Drugs Affected: What Patients Need to Know

Lynparza (olaparib) — AstraZeneca

This PARP inhibitor treats two prostate cancer populations:

  • Men with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone
  • Men with HRR gene-mutated mCRPC who progressed after enzalutamide or abiraterone

FDA approval for Lynparza plus abiraterone in BRCA-mutated mCRPC was based on the Phase III PROpel trial, which showed highly clinically meaningful improvements in both radiographic progression-free survival and overall survival versus abiraterone alone. The combination reduced the risk of disease progression or death by 34% versus abiraterone alone.

Current assistance: AstraZeneca offers programs reducing out-of-pocket costs to as little as $0 per 30-day supply with savings up to $26,000 per year for eligible commercially insured patients. Call Access 360 at 844-275-2360.

Xtandi (enzalutamide) — Pfizer/Astellas

Pfizer jointly develops and commercializes Xtandi with Astellas Pharma. Xtandi became the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog in nonmetastatic castration-sensitive prostate cancer in November 2023.

It is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

The drug's high cost has been controversial. Xtandi was developed at UCLA with support from grants from the U.S. National Institutes of Health and Department of Defense, yet the U.S. average wholesale price per patient was $189,800 per year in January 2022, compared to costs as much as 80% lower in other countries.

Current assistance: Eligible commercially insured patients may qualify for the Xtandi Patient Savings Program.

Talzenna (talazoparib) — Pfizer

Talzenna in combination with Xtandi is the first PARP inhibitor plus androgen receptor pathway inhibitor combination to demonstrate statistically significant improvement in overall survival in mCRPC patients regardless of HRR mutation status. In HRR-mutated mCRPC patients, median overall survival was 45.1 months with the combination versus 31.1 months with Xtandi alone—a 38% reduction in the risk of death.

Erleada (apalutamide) — Johnson & Johnson

Erleada is an androgen receptor inhibitor indicated for non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. In the largest head-to-head real-world study in metastatic castration-sensitive prostate cancer, Erleada reduced risk of death by 23% at 24 months compared to enzalutamide.

Note: Johnson & Johnson has not yet announced an MFN pricing deal, though Trump stated he aims to strike pricing deals with other major drugmakers in the weeks ahead.

The Skeptics' View: Will Patients Actually Benefit?

Several healthcare policy experts and economists have raised concerns about the agreements' real-world impact.

Rachel Sachs, a law professor at Washington University, stated that confidential agreements are not a good way to make public policy, adding that it's unclear what exactly the drugmakers have agreed to, who will enforce the provisions, and who is likely to benefit.

The Medicaid impact may be limited. Medicaid already enjoys 'best-price' protection, receiving the lowest prices charged to any commercial payer in the United States, so the actual impact of most-favored-nation pricing could be muted. Medicaid enrollees already pay little to nothing for medications.

For the TrumpRx website, the deals would only be accessible for patients not using their health insurance, and even then, the discounted medicines might not be affordable because they're based on high drug list prices, with consumers with health insurance potentially paying less at the pharmacy counter.

Research at the USC Schaeffer Center reveals about 70% of global pharmaceutical profits flow from the U.S. market, and facing a choice between deep cuts in their U.S. pricing or loss of overseas markets, many firms could pull out from overseas markets, leaving U.S. consumers with the same prices and future generations with less innovation.

Silver Lining: Medicare Part D Cap

Separate from the MFN deals, a significant Medicare change took effect in 2025. Medicare Part D patients now pay no more than $2,000 a year in out-of-pocket costs for all prescription medicines, with the option to spread costs into monthly payments.

For a prostate cancer patient on Xtandi who previously faced thousands of dollars in monthly costs, this cap represents guaranteed, enforceable savings—unlike the voluntary manufacturer agreements.

Action Steps for Patients

1. Don't change your current treatment. These agreements don't affect existing prescriptions. Continue medications as prescribed.

2. Review your coverage now:

  • Understand your current out-of-pocket costs
  • Determine eligibility for manufacturer assistance programs
  • Compare your insurance costs to what direct purchase might cost when TrumpRx launches

3. Consider genetic testing: If you haven't been tested for BRCA or HRR mutations, ask your oncologist if testing is appropriate. Results determine eligibility for Lynparza and Talzenna combination therapies.

4. Monitor TrumpRx.gov: When the website launches in early 2026, compare direct-to-consumer pricing with your insurance coverage. Remember: cash-pay prices through TrumpRx may still exceed your insurance copays.

5. Explore current assistance programs:

  • Lynparza: AstraZeneca Access 360, 844-275-2360
  • Xtandi: Xtandi Patient Savings Program, visit xtandipricing.com
  • Talzenna: Pfizer patient assistance programs
  • Erleada: Visit erleada.com for program information

6. Ask about Medicare Part D: If you're on Medicare, ensure you understand the $2,000 annual cap and monthly payment option.

The Bottom Line

These agreements represent the most significant federal intervention in drug pricing in years, potentially affecting billions of dollars in pharmaceutical sales. Whether they translate to meaningful savings for prostate cancer patients depends on multiple factors: your insurance status, which drugs you need, manufacturer program eligibility, and how aggressively your state's Medicaid program negotiates.

The deals' structure—voluntary agreements with confidential terms and no apparent enforcement mechanisms—leaves many questions unanswered. Patients with commercial insurance may see little change, while those on Medicaid may already have better prices. The biggest winners could be uninsured patients or those with high deductibles, assuming TrumpRx prices truly undercut retail pharmacy costs.

Work closely with your oncology team, pharmacist, and financial counselor to navigate these changes and ensure you receive the most cost-effective, clinically appropriate care for your specific situation.

Key Sources

Policy Announcements:

  • The White House. (2025, October 10). Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients. https://www.whitehouse.gov/fact-sheets/2025/10/
  • U.S. Department of Health and Human Services. (2025, May 20). HHS, CMS Set Most-Favored-Nation Pricing Targets. https://www.hhs.gov/press-room/cms-mfn-lower-us-drug-prices.html

News Coverage:

  • Luhby, T. (2025, October 10). Trump announces deal with AstraZeneca aimed at lowering drug prices. CNN Politics. https://www.cnn.com/2025/10/10/politics/lower-drug-prices-trump-announcement
  • Weissert, W. (2025, October 11). AstraZeneca agrees to lower drug prices in Medicaid deal. San Diego Union Tribune.
  • Wroblewski, M. (2025, October 10). AstraZeneca reaches deal on drug prices with President Trump. NPR. https://www.npr.org/sections/shots-health-news/2025/10/10/nx-s1-5571070/astrazeneca-trump-drug-prices

Clinical Data:

  • AstraZeneca. (2023, June 1). Lynparza plus abiraterone approved in the US for BRCA-mutated mCRPC. https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer.html
  • Pfizer. (2025, February 13). Pfizer's TALZENNA in Combination with XTANDI Improves Survival Outcomes. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-talzennar-combination-xtandir-improves-survival
  • Johnson & Johnson. (2025, July 18). ERLEADA demonstrates improvement in overall survival compared to enzalutamide. https://www.jnj.com/media-center/press-releases/

Pricing Analysis:

  • Health Policy Watch. (2022, February 21). High Cost Of Prostate Cancer Drug Re-Ignites Demands For Government Action. https://healthpolicy-watch.news/us-prostate-cancer-drug-price-re-ignites-demand-for-government-action/
  • Lakdawalla, D. & Goldman, D. (2025, April 14). 'Most-Favored Nation' Drug Pricing Has Three Significant Problems. USC Schaeffer Center. https://schaeffer.usc.edu/research/most-favored-nation-drug-pricing-has-three-significant-problems/
  • Oncology News Central. (2025, February 7). Public Dollars, Private Profits? Cancer Drug's Cost Sky High Despite Taxpayer Funding. https://www.oncologynewscentral.com/drug/public-dollars-private-profits-cancer-drugs-cost-sky-highdespite-taxpayer-funding

*Complete source list with 80+ references available upon request.

This article provides information about drug pricing developments and should not replace medical or financial advice. Consult your oncologist, healthcare team, or financial counselor about your specific situation. Contact IPCSG for additional resources and support.

Comprehensive Source List

News Coverage of Drug Pricing Deals:

  1. Weissert, W. (2025, October 11). AstraZeneca agrees to lower drug prices in Medicaid deal. San Diego Union Tribune. https://enewspaper.sandiegouniontribune.com/

  2. Goldberg, E. (2025, October 10). Trump reaches drug pricing deal with AstraZeneca. CNBC. https://www.cnbc.com/2025/10/10/trump-astrazeneca-drug-pricing-deal.html

  3. Luhby, T. (2025, October 10). Trump announces deal with AstraZeneca aimed at lowering drug prices. CNN Politics. https://www.cnn.com/2025/10/10/politics/lower-drug-prices-trump-announcement

  4. Associated Press. (2025, October 10). AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal. ABC News. https://abcnews.go.com/Politics/wireStory/astrazeneca-agrees-lower-drug-prices-medicaid-trump-administration-126418888

  5. Wroblewski, M. (2025, October 10). AstraZeneca reaches deal on drug prices with President Trump. NPR Shots - Health News. https://www.npr.org/sections/shots-health-news/2025/10/10/nx-s1-5571070/astrazeneca-trump-drug-prices

  6. Murphy, T., et al. (2025, October 10). Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join "TrumpRx" site. CBS News. https://www.cbsnews.com/news/trump-astrazeneca-deal-drug-prices-medicaid-trumprx/

  7. Owens, C. (2025, October 10). Trump's drug prices: AstraZeneca agrees to deal. Axios. https://www.axios.com/2025/10/10/trump-drug-prices-astra-zeneca

  8. MSNBC. (2025, October 10). Trump strikes drug-pricing deal with pharma giant AstraZeneca. https://www.msnbc.com/msnbc/news/trump-strikes-drug-pricing-deal-pharma-giant-astrazeneca-rcna236905

Lynparza Clinical Data and Information:

9-21. [AstraZeneca sources from previous list remain the same] see below

Xtandi (Pfizer/Astellas) Information:

  1. Pfizer. (2025, June 13). Pfizer Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI. https://www.pfizer.com/news/announcements/pfizer-provides-update-us-regulatory-review-talzenna-combination-xtandi-broader

  2. Becker, Z. (2025, July 10). Pfizer, Astellas boost case for Xtandi in early-stage prostate cancer with combo survival win. Fierce Pharma. https://www.fiercepharma.com/pharma/pfizer-astellas-xtandi-bolsters-its-early-stage-prostate-cancer-case-mixed-bag-survival-win

  3. Pfizer & Astellas. (2023, November 16). Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-astellas-xtandir-approved-us-fda-earlier

  4. Pfizer. (2025, February 13). Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-talzennar-combination-xtandir-improves-survival

46-47. Pfizer & Astellas. (2025, May 22 & July 10). Long-term survival data and combination therapy results. https://www.pfizer.com/news/

  1. Silverman, E. (2024, April 10). Biden administration urged to license prostate cancer drug patents in a bid to lower its cost. STAT News. https://www.statnews.com/pharmalot/2024/04/09/xtandi-patents-prostate-cancer-pfizer-astellas-hhs-cms/

Johnson & Johnson Erleada Information:

52-61. [Multiple sources on Erleada approvals, trials, and market competition]

White House Policy Documents:

  1. The White House. (2025, May 12). Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/

  2. The White House. (2025, September 30). Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients. https://www.whitehouse.gov/fact-sheets/2025/09/

  3. The White House. (2025, October 10). Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients. https://www.whitehouse.gov/fact-sheets/2025/10/

  4. The White House. (2025, July 31). Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs. https://www.whitehouse.gov/fact-sheets/2025/07/

  5. U.S. Department of Health and Human Services. (2025, May 20). HHS, CMS Set Most-Favored-Nation Pricing Targets. https://www.hhs.gov/press-room/cms-mfn-lower-us-drug-prices.html

TrumpRx Website Information:

32-41. [Multiple sources on TrumpRx.gov functionality and launch plans]

Drug Pricing Analysis:

  1. Lakdawalla, D. & Goldman, D. (2025, April 14). 'Most-Favored Nation' Drug Pricing Has Three Significant Problems. USC Schaeffer Center. https://schaeffer.usc.edu/research/most-favored-nation-drug-pricing-has-three-significant-problems/

  2. Goldman, D. (2025, October 5). Drug Prices: Will the New Pfizer Deal Lower Costs for Americans? National Academy of Medicine. https://nam.edu/news-and-insights/trump-pfizer-drug-prices-deal/

Drug Pricing Data:

  1. Health Policy Watch. (2022, February 21). High Cost Of Prostate Cancer In United States Drug Re-Ignites Demands For Government Action. https://healthpolicy-watch.news/us-prostate-cancer-drug-price-re-ignites-demand-for-government-action/

  2. PIRG. (2022, December 1). Solve the high cost of Xtandi using "March-In" rights. https://pirg.org/updates/solve-the-high-cost-of-xtandi-treatment-for-prostate-cancer-using-march-in-rights/

  3. Knowledge Ecology International. (2023, March 28). Xtandi: 2021-2022 Request to US Department of Health and Human Services. https://www.keionline.org/xtandi2021

  4. Astellas. XTANDI® (enzalutamide) Pricing Information. https://www.xtandipricing.com/

  5. Oncology News Central. (2025, February 7). Public Dollars, Private Profits? Cancer Drug's Cost Sky High Despite Taxpayer Funding. https://www.oncologynewscentral.com/drug/public-dollars-private-profits-cancer-drugs-cost-sky-highdespite-taxpayer-funding

  6. iHealthcare Analyst. (2025, February 10). Prostate Cancer Therapeutics Market and Forecast 2025-2031. https://www.ihealthcareanalyst.com/report/prostate-cancer-therapeutics-market/

This article provides general information about drug pricing developments and should not be construed as medical or financial advice. For questions about how these developments may affect your specific treatment or costs, please consult with your oncologist, healthcare team, or financial counselor. Contact the IPCSG at [contact information] for additional resources and support.

AstraZeneca commits to lower drug prices for Medicaid patients and direct-to-consumer sales

October 11, 2025 — IPCSG Newsletter

In a significant development that may affect access to critical prostate cancer treatments, AstraZeneca became the second major pharmaceutical manufacturer to announce an agreement to lower prescription drug costs for Medicaid under a deal with the Trump administration, following a similar agreement with Pfizer announced in late September.

The Deal's Key Components

Under the agreement, AstraZeneca will charge most-favored-nation pricing to Medicaid while guaranteeing such pricing on newly launched drugs, which involves matching the lowest price offered in other developed nations. The announcement was made on Friday, October 10, 2025, at the White House with AstraZeneca CEO Pascal Soriot and President Donald Trump.

AstraZeneca stated in a press release that it will allow eligible patients with prescriptions for chronic diseases to purchase drugs directly at a discount of up to 80% off list prices. Additionally, the company announced Thursday that it would spend $4.5 billion on a new manufacturing plant near Charlottesville, Virginia, as part of $50 billion in investments the company plans to make in the U.S. by 2030.

Implications for Prostate Cancer Patients

AstraZeneca manufactures Lynparza (olaparib), a PARP inhibitor that has become an important treatment option for certain prostate cancer patients. The company makes a range of cancer treatments including Lynparza, an oral treatment for ovarian cancer, among others, and these drugs brought in a total of more than $7.5 billion in U.S. sales last year.

Lynparza's Role in Prostate Cancer Treatment

Lynparza is currently approved in the United States for patients with:

  • BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) when used in combination with abiraterone and prednisone or prednisolone
  • HRR gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone

The FDA approval for Lynparza plus abiraterone in BRCA-mutated mCRPC was based on a subgroup analysis of the Phase III PROpel trial, which showed highly clinically meaningful improvements in both radiographic progression-free survival and overall survival versus abiraterone alone in patients with BRCA mutations.

In the PROpel trial's predefined interim analysis, Lynparza in combination with abiraterone reduced the risk of disease progression or death by 34% versus abiraterone alone in the overall trial population.

How the TrumpRx Website Will Work

The Trump administration has put up a landing page for its new website, TrumpRX.gov, where people will be able to buy drugs directly from manufacturers, according to officials, with both Pfizer and AstraZeneca offering medications through the site.

The government-operated website will not directly sell or distribute medications but is designed to function as a search portal where consumers can look up their prescriptions and, if a drug is part of the program, they will be redirected to the pharmaceutical manufacturer's own direct-to-consumer platform to complete the purchase.

Under the deal, AstraZeneca will also list "all primary care medications" on the TrumpRx website, and Centers for Medicare and Medicaid Services Administrator Mehmet Oz stated the website is set to launch early next year.

Important Considerations for Patients

Who May Benefit

The direct-to-consumer pricing through TrumpRx is designed for patients who:

  • Are paying out-of-pocket without insurance
  • Have high deductibles
  • Are on Medicaid (who will receive most-favored-nation pricing)

Limitations and Questions

Experts caution that Medicaid already enjoys 'best-price' protection in the sense that they receive the lowest prices charged to any commercial payer in the United States, so the actual impact of most-favored-nation pricing could be muted. Additionally, some industry experts have questioned whether Americans will feel much relief from these agreements and whether the companies are really making notable concessions.

The website deals would only be accessible for patients not using their health insurance, and even then, the discounted medicines might not be affordable because they're based on high drug list prices, with consumers with health insurance potentially paying less at the pharmacy counter.

Current Pricing and Assistance Programs

Lynparza is currently a specialty medication with significant costs. The 150 mg Lynparza oral tablet is priced from $8,486.56 for 60 tablets in the United States. However, AstraZeneca currently offers patient assistance programs that may reduce out-of-pocket costs to as little as $0 per 30-day supply with savings of up to $26,000 per year for eligible commercially insured patients.

What Patients Should Do

  1. Continue current treatment plans: This agreement does not change current prescriptions or treatment protocols
  2. Consult with your oncologist: Discuss whether you might be eligible for BRCA testing if not already completed, as this determines eligibility for Lynparza combination therapy
  3. Review your insurance coverage: Understand how your current insurance covers Lynparza and compare that to the upcoming direct-to-consumer options when TrumpRx launches
  4. Explore existing assistance programs: Contact AstraZeneca's Access 360 program at 844-275-2360 or visit their specialty savings website to determine current eligibility for patient assistance
  5. Stay informed: Monitor for the official launch of TrumpRx.gov in early 2026 and evaluate whether direct purchase would be more affordable than your current insurance coverage

The Broader Context

These agreements build on an executive order Trump signed in May that set a deadline for drugmakers to electively lower prices or face new limits on what the government will pay. Other large drug companies are expected to reach similar deals in the coming weeks.

One of the AstraZeneca drugs was already subject to price reductions due to a Medicare negotiating strategy implemented under President Biden, highlighting that multiple policy approaches are being used to address drug pricing.

Looking Ahead

While this agreement represents a significant policy development in the ongoing effort to reduce drug costs in the United States, the actual impact on individual patients will vary considerably based on insurance status, specific drug needs, and eligibility for various assistance programs. Prostate cancer patients using or considering Lynparza should work closely with their healthcare teams and financial counselors to understand how these changes may affect their specific situations.

Sources

  1. Weissert, W. (2025, October 11). AstraZeneca agrees to lower drug prices in Medicaid deal. San Diego Union Tribune. https://enewspaper.sandiegouniontribune.com/html5/reader/production/

  2. Goldberg, E. (2025, October 10). Trump reaches drug pricing deal with AstraZeneca. CNBC. https://www.cnbc.com/2025/10/10/trump-astrazeneca-drug-pricing-deal.html

  3. Luhby, T. (2025, October 10). Trump announces deal with AstraZeneca aimed at lowering drug prices. CNN Politics. https://www.cnn.com/2025/10/10/politics/lower-drug-prices-trump-announcement

  4. Associated Press. (2025, October 10). AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal. ABC News. https://abcnews.go.com/Politics/wireStory/astrazeneca-agrees-lower-drug-prices-medicaid-trump-administration-126418888

  5. Diamond, D. (2025, October 10). Trump announces drug-price deal with AstraZeneca. The Washington Post. https://www.washingtonpost.com/politics/2025/10/10/trump-drug-prices-astrazeneca/

  6. MSNBC. (2025, October 10). Trump strikes drug-pricing deal with pharma giant AstraZeneca. https://www.msnbc.com/msnbc/news/trump-strikes-drug-pricing-deal-pharma-giant-astrazeneca-rcna236905

  7. Wroblewski, M. (2025, October 10). AstraZeneca reaches deal on drug prices with President Trump. NPR Shots - Health News. https://www.npr.org/sections/shots-health-news/2025/10/10/nx-s1-5571070/astrazeneca-trump-drug-prices

  8. Murphy, T., et al. (2025, October 10). Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join "TrumpRx" site. CBS News. https://www.cbsnews.com/news/trump-astrazeneca-deal-drug-prices-medicaid-trumprx/

  9. U.S. News & World Report. (2025, October 10). AstraZeneca Agrees to Lower Drug Prices for Medicaid Under Trump Administration Deal. https://www.usnews.com/news/politics/articles/2025-10-10/astrazeneca-agrees-to-lower-drug-prices-for-medicaid-under-trump-administration-deal

  10. Owens, C. (2025, October 10). Trump's drug prices: AstraZeneca agrees to deal. Axios. https://www.axios.com/2025/10/10/trump-drug-prices-astra-zeneca

  11. Boston.com. (2025, October 11). AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal. https://www.boston.com/news/business/2025/10/11/astrazeneca-agrees-to-lower-drug-prices-for-medicaid-under-trump-administration-deal/

  12. AstraZeneca. (2023, June 1). Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. AstraZeneca Media Centre. https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer.html

  13. AstraZeneca US. (2023, June 1). LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. https://www.astrazeneca-us.com/media/press-releases/2023/lynparza-olaparib-plus-abiraterone-approved-in-the-us-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer.html

  14. AstraZeneca. (2023, February 16). AstraZeneca and MSD present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium. AstraZeneca Media Centre. https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html

  15. AstraZeneca. (2023, April 28). Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer. AstraZeneca Media Centre. https://www.astrazeneca.com/media-centre/press-releases/2023/odac-vote-on-lynparza-combo-in-prostate-cancer.html

  16. Merck. (2023, March 8). Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib). https://www.merck.com/news/merck-and-astrazeneca-provide-update-on-us-regulatory-review-of-lynparza-olaparib-for-use-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-the-treatment-of-metastatic-castrat/

  17. AstraZeneca. (2022, February 14). Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer. AstraZeneca Media Centre. https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer.html

  18. LYNPARZA® Official Patient Website. Metastatic Prostate Cancer. https://www.lynparza.com/prostate-cancer/home.html

  19. AstraZeneca. (2022, December 21). Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer. AstraZeneca Media Centre. https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-prostate-cancer.html

  20. AstraZeneca. (2023, March 2). Update on US regulatory review of Lynparza in combination with abiraterone for metastatic castration-resistant prostate cancer. AstraZeneca Media Centre. https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-regulatory-review-of-lynparza-in-combination-with-abiraterone-for-mcrpc.html

  21. LYNPARZA® Official Patient Website. https://www.lynparza.com/

  22. GoodRx. (2025). Lynparza 2025 Prices, Coupons & Savings Tips. https://www.goodrx.com/lynparza

  23. Medical News Today. (2023, September 24). Lynparza cost 2025: Coupons and more. https://www.medicalnewstoday.com/articles/drugs-lynparza-cost

  24. Drugs.com. Lynparza Prices, Coupons, Copay Cards & Patient Assistance. https://www.drugs.com/price-guide/lynparza

  25. PharmacyChecker.com. Lynparza Prices - U.S. & International. https://www.pharmacychecker.com/lynparza/150+mg/

  26. PharmacyChecker.com. Olaparib (Lynparza) Prices - U.S. & International. https://www.pharmacychecker.com/olaparib/

27-31. [Additional sources for pricing and patient information]

32-41. [Sources regarding TrumpRx.gov website]:

  1. CBS News. (2025, October 10). Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join "TrumpRx" site. https://www.cbsnews.com/news/trump-astrazeneca-deal-drug-prices-medicaid-trumprx/

  2. GovFacts. (2025, October). TrumpRx: How the Drug Pricing Program Works. https://govfacts.org/explainer/trumprx-how-the-drug-pricing-program-works/

  3. Al Jazeera. (2025, October). What is Trump's new TrumpRx website and will it bring medicine prices down? https://www.aljazeera.com/news/2025/10/3/what-is-trumps-new-trumprx-website-and-will-it-bring-medicine-prices-down

  4. NPR. (2025, September 30). TrumpRx website for drug discounts is part of Pfizer deal. Shots - Health News. https://www.npr.org/sections/shots-health-news/2025/09/30/nx-s1-5558432/drug-prices-trumprx-pfizer

  5. Demissie, H., Murray, I., & Strauss, E.M. (2025, September 30). Trump announces 'TrumpRx' website for pharmaceutical drugs after Pfizer deal. ABC News. https://abcnews.go.com/US/trump-announces-trumprx-website-pharmaceutical-drugs-after-pfizer/story?id=126094779

  6. Fierce Healthcare. (2025, October). White House announces new prescription drug website, TrumpRx. https://www.fiercehealthcare.com/providers/white-house-announces-new-prescription-drug-website-trumprx

  7. Dayen, D. (2025, October 2). 'TrumpRx' Is Another Pretend Solution for High Drug Prices. The American Prospect. https://prospect.org/health/2025-10-02-trumprx-pretend-solution-high-drug-prices/

  8. Newsweek. (2025, September 30). What is "TrumpRx"? White House unveils new prescription drug website. https://www.newsweek.com/donald-trump-rx-pfizer-white-house-medicine-10805621

  9. Axios. (2025, October 1). Inside the TrumpRx website and its unusual launch. https://www.axios.com/2025/10/01/trumprx-website-drug-prices-trump-pfizer

  10. CNN. (2025, September 30). Trump announces 'TrumpRx' site for discounted drugs. https://www.cnn.com/2025/09/30/politics/pfizer-drug-prices-trump

For questions about this article or to discuss how these developments may affect your treatment, please consult with your oncologist or contact the IPCSG at [contact information].

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

Image
  Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology SAN DIEGO, May 21, 2025 - Dr. Christopher Kane, a distinguished urologist and Professor of Urology at UC San Diego Health, has been appointed Chairman of the American Board of Urology (ABU), the organization announced today. Dr. Kane, who has served as CEO of UC San Diego Health Physician Group and Dean of Clinical Affairs at the UC San Diego School of Medicine, brings decades of experience in urologic oncology and leadership to this prestigious national position. Extensive Academic and Research Background Dr. Kane earned his medical degree from Uniformed Services University in Bethesda, Maryland, followed by a residency in urology at the Naval Medical Center San Diego and a fellowship in urologic oncology at the National Cancer Institute. He joined the UCSD faculty in 2007 after serving as a Navy physician for 12 years. As the C. Lowell and JoEllen Parsons Endowed Chair in Urology, Dr. ...
Read more

PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course

Image
  Interactive Graphic PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course Landmark FDA approval expands access to radioligand therapy while new research explores next-generation treatments By [Your Name] for the IPCSG Newsletter The landscape of prostate cancer treatment has undergone a seismic shift in recent months, with groundbreaking advances in prostate-specific membrane antigen (PSMA)-targeted therapies offering new hope to patients across different stages of the disease. Most significantly, the FDA's March 2025 expansion of Pluvicto (lutetium-177-PSMA-617) approval now allows treatment before chemotherapy, potentially tripling the number of eligible patients. Major FDA Approval Expands Treatment Access On March 28, 2025, the FDA approved a crucial expansion of Pluvicto's indication, allowing its use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen recepto...
Read more